The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Nitric oxide donors: Novel cancer therapeutics (Review)
Open accessAbstract
The development of cancer cell resistance to various cytotoxic stimuli continues to be a major challenge in oncology and novel therapeutic approaches are urgently needed. Nitric oxide (NO) is emerging as a potential anti-oncogenic agent to overcome tumor cell resistance to conventional therapeutic agents. NO is a ubiquitous, water-soluble, free radical gas that exerts a wide range of biological effects. The actions of nitric oxide are highly variable in oncology with reports in the literature on both sides of the spectrum as an anti-neoplastic vs. a pro-neoplastic agent. The final activity of NO in oncology is dependent on its working microenvironment, including the type of cell exposed to the compound, the redox state of the reaction, as well as the final intracellular concentration and the duration of intracellular exposure to nitric oxide. There is, however, no unifying mechanistic explanation for the biphasic role of nitric oxide in oncology. Nitric oxide donors mimic continuous production of NO in a wide range of time intervals (seconds to days). Thus, multiple biological and (pro- vs. anti-) neoplastic responses are elicited from NO donors depending on the half-life and the type of cell exposed to the compound. The large variety of nitric oxide donors may serve as a tool to explore the wide range of oncologic properties of NO in cancer. In the present report, we discuss classic nitric oxide donors and their potential therapeutic roles as cytotoxic agents or chemo-radio or -immune-sensitizing compounds in the treatment of drug-resistant cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Wink, D. A., & Mitchell, J. B. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00092-6 · Cited by 1,606
Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite
Hibbs, J. B., Taintor, R. R., & Vavrin, Z. (1987) · Science · doi:10.1126/science.2432665 · Cited by 1,527
Nitric oxide donors: chemical activities and biological applications
Wang, P. G., Xian, M., Tang, X., Wu, X., Wen, Z., Cai, T., & Janczuk, A. J. (2002) · Chemical Reviews · doi:10.1021/cr000040l · Cited by 1,337
Stuehr, D. J., & Marletta, M. A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.22.7738 · Cited by 1,126
The Production of Malignant Primary Hepatic Tumours in the Rat by Feeding Dimethylnitrosamine
Magee, P. N., & Barnes, J. M. (1956) · British Journal of Cancer · doi:10.1038/bjc.1956.15 · Cited by 900
Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin
Lechner, M., Lirk, P., & Rieder, J. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.004 · Cited by 410
Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia
Sogawa, K., Numayama-Tsuruta, K., Ema, M., Abe, M., Abe, H., & Fujii-Kuriyama, Y. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7368 · Cited by 224
Ambs, S., Bennett, W. P., Merriam, W. G., Ogunfusika, M. O., Oser, S. M., Harrington, A. M., Shields, P. G., Felley-Bosco, E., Hussain, S. P., & Harris, C. C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.86 · Cited by 166
Cited by
Reactive oxygen species and cancer paradox: To promote or to suppress?
Galadari, S., Rahman, A., Pallichankandy, S., & Thayyullathil, F. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.004 · Cited by 893
Metal–organic frameworks as potential drug carriers
Huxford, R. C., Della Rocca, J., & Lin, W. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.12.012 · Cited by 840
Gasotransmitters in cancer: from pathophysiology to experimental therapy
Szabo, C. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.1 · Cited by 717
Nitric oxide and cancer: a review
Korde Choudhari, S., Chaudhary, M., Bagde, S., Gadbail, A. R., & Joshi, V. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-118 · Cited by 634
The dual role of iNOS in cancer
Vannini, F., Kashfi, K., & Nath, N. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.009 · Cited by 524
Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects
Huang, Z., Fu, J., & Zhang, Y. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01672 · Cited by 406
Gas-Mediated Cancer Bioimaging and Therapy
Chen, L., Zhou, S.-F., Su, L., & Song, J. (2019) · ACS Nano · doi:10.1021/acsnano.9b04954 · Cited by 343
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Pinzón‐Daza, M., Garzón, R., Couraud, P., Romero, I., Weksler, B., Ghigo, D., Bosia, A., & Riganti, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02103.x · Cited by 84
Metadata
- Authors
- Huerta
- Venue
- international Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 1992-01-01
- Volume
- 33
- Issue
- 5
- Pages
- 909-27
- ISSN
- 1019-6439 (ISSN-L)
- OpenAlex
- W2047963812
- Cited by
- 222
- References
- 9
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.